Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice
Top Cited Papers
Open Access
- 18 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Vaccines
- Vol. 6 (1), 1-12
- https://doi.org/10.1038/s41541-021-00345-0
Abstract
Human malaria affects the vast majority of the world’s population with the Plasmodium falciparum species causing the highest rates of morbidity and mortality. With no licensed vaccine and leading candidates achieving suboptimal protection in the field, the need for an effective immunoprophylactic option continues to motivate the malaria research community to explore alternative technologies. Recent advances in the mRNA discipline have elevated the long-neglected platform to the forefront of infectious disease research. As the immunodominant coat protein of the invasive stage of the malaria parasite, circumsporozoite protein (PfCSP) was selected as the antigen of choice to assess the immunogenic and protective potential of an mRNA malaria vaccine. In mammalian cell transfection experiments, PfCSP mRNA was well expressed and cell associated. In the transition to an in vivo murine model, lipid nanoparticle (LNP) encapsulation was applied to protect and deliver the mRNA to the cell translation machinery and supply adjuvant activity. The immunogenic effect of an array of factors was explored, such as formulation, dose, number, and interval of immunizations. PfCSP mRNA-LNP achieved sterile protection against infection with two P. berghei PfCSP transgenic parasite strains, with mRNA dose and vaccination interval having a greater effect on outcome. This investigation serves as the assessment of pre-erythrocytic malaria, PfCSP mRNA vaccine candidate resulting in sterile protection, with numerous factors affecting protective efficacy, making it a compelling candidate for further investigation.Keywords
Funding Information
- United States Department of Defense | United States Army | U.S. Military Academy
- United States Agency for International Development
- U.S. Military Infectious Diseases Research Program (MIDRP) U.S. Agency for International Development
- Acuitas Therapeutics
This publication has 95 references indexed in Scilit:
- Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparumMalaria Journal, 2013
- Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccineMalaria Journal, 2013
- Protective Antibody and CD8+ T-Cell Responses to the Plasmodium falciparum Circumsporozoite Protein Induced by a Nanoparticle VaccinePLOS ONE, 2012
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie, 2012
- Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase LNucleic Acids Research, 2011
- Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacyMalaria Journal, 2010
- Role of 5′‐ and 3′‐untranslated regions of mRNAs in human diseasesBiology of the Cell, 2009
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- Interleukin‐10: new perspectives on an old cytokineImmunological Reviews, 2008
- Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against InfluenzaClinical and Vaccine Immunology, 2006